rHuman FLt3 Active, Human cytokinesand growth factors
- Known as:
- rHuman FLt3 Active, Human cytokinesand growth factors
- Catalog number:
- RF0039-10
- Product Quantity:
- 10
- Category:
- -
- Supplier:
- Agren
- Gene target:
- rHuman FLt3 Active Human cytokinesand growth factors
Related genes to: rHuman FLt3 Active, Human cytokinesand growth factors
- Gene:
- FLT3 NIH gene
- Name:
- fms related tyrosine kinase 3
- Previous symbol:
- -
- Synonyms:
- STK1, FLK2, CD135
- Chromosome:
- 13q12.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-07-30
- Date modifiied:
- 2019-04-23
Related products to: rHuman FLt3 Active, Human cytokinesand growth factors
Related articles to: rHuman FLt3 Active, Human cytokinesand growth factors
- - Source: PubMed
Publication date: 2026/01/15
Kayser SabineSchlenk Richard F - Not available. - Source: PubMed
Publication date: 2026/01/15
Russell Nigel HLewis Katie D - Acute myeloid leukemia (AML) is an aggressive hematopoietic cancer with poor survival outcomes. Despite improvements with recent FMS-like tyrosine kinase 3 (FLT3) inhibitors, resistance is common, and responses are short. Dapolsertib (MEN1703) is a novel, first-in-class dual inhibitor of PIM (proviral integration site for Moloney murine leukemia virus) and FLT3 kinases, with activity in both -mutated and wild-type cells. A phase 1/2 open-label, multicenter, dose-escalation study (DIAMOND-01) investigated the maximum tolerated dose (MTD) of single-agent dapolsertib and assessed its safety, efficacy, pharmacokinetic (PK) profile, pharmacodynamic biomarkers, and genomics in patients with AML with no standard therapeutic options available. Seventy-three patients received oral doses of dapolsertib ranging from 25 to 150 mg per day (14 consecutive days over 21-day cycles). In the dose-escalation phase, the MTD was 125 mg and was selected for dose expansion. The most common grade ≥3 adverse events in patients receiving 125 mg were pneumonia (38%), thrombocytopenia (30%), and anemia (27%); most of these events were deemed not treatment related. For patients receiving 125 mg dapolsertib (n = 55), the overall response rate was 9%, with a median 2.07-month duration of response, and 4 of 5 responses were observed in patients with isocitrate dehydrogenase 1 ()/ mutations. PK analysis indicated rapid absorption of oral dapolsertib, an elimination half-life suitable for once daily dosing and a PK independent of formulation and IDH mutational status. Pharmacodynamic activity was confirmed in 50% of evaluable patients. Overall, dapolsertib demonstrated modest single-agent activity in patients with AML. This trial was registered at www.clinicaltrials.gov as #NCT03008187. - Source: PubMed
Publication date: 2025/10/24
Martinelli GiovanniSolomon Scott RMukherjee SudiptoSantoro ArmandoStrickland Stephen AVives SusanaRavandi FarhadWalter Roland BCook Rachel JLech-Maranda EwaCalbacho MariaWierzbowska AgnieszkaMarconi GiovanniAcuña-Cruz EvelynCano-Ferri IsabelBertolini FrancescoRzymski TomaszPaoli AlessandroMerlo Giovanni MarinoAuriol Faten KoraichiZicari SoniaGalleu AntonioGupta IraMontesinos Pau - NPM1-mutated (NPM1-mut) acute myeloid leukemia (AML) is generally associated with a more favorable outcome, although the presence of additional gene mutations can influence patient prognosis. We analyzed intensively-treated adult NPM1-mut AML patients included in the HARMONY Alliance database. A newly developed risk classification, which included combinations of co-mutations in FLT3-ITD, DNMT3A, IDH1/IDH2, and TET2 genes, was applied to a training cohort of NPM1-mut AML patients included in clinical trials (n = 1001), an internal validation cohort more representative of real-world settings (n = 762), and an external validation cohort enrolled in UK-NCRI trials (n = 585). The HARMONY classification considered 51.8% of the NPM1-mut AML training cohort patients as favorable, 24.8% as intermediate, and 23.4% as adverse risk, with median overall survival (OS) of 14.4, 2.2, and 0.9 years, respectively; p < 0.001), thereby reclassifying 42.7% of NPM1-mut patients into a different European LeukemiaNet (ELN) 2022 risk category. These results were confirmed both in an internal and external validation cohort. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1) showed the highest benefit in the NPM1-mut adverse-risk subgroup. The HARMONY classification provides the basis for a refined genetic risk stratification for adult NPM1-mut AML with potential clinical impact on allo-HSCT decision-making. - Source: PubMed
Publication date: 2026/01/14
Hernández-Sánchez AlbertoVillaverde Ramiro ÁngelaSträng EricTurki Amin TAbáigar MaríaVersluis JurjenThomas IanSobas MartaMartínez Elicegui JavierCastellani GastoneBenner AxelAzibeiro RaúlTettero Jesse MMecklenbrauck RabeaMartínez-López JoaquínPratcorona MartaMills Ken ISanz GuillermoVoso Maria TeresaSören LehmannRöllig ChristophThiede ChristianMetzeler Klaus HDöhner KonstanzeHeuser MichaelHaferlach TorstenValk Peter JmRussell NigelHernández-Rivas Jesús MaríaHuntly BrianOssenkoppele GertDöhner HartmutBullinger Lars - This study aimed to investigate the prognostic value of FLT3-ITD molecular features such as allelic ratio (AR), variant allele frequency (VAF), insertion length, insertion number and insertion site in patients with de novo acute myeloid leukemia (AML). Next-generation sequencing (NGS) was used to detect FLT3-ITD mutations in 170 patients with newly diagnosed AML (except acute promyelocytic leukemia). FLT3-ITD patients with longer insertion lengths, higher allelic ratio, and more mutations had relatively shorter overall survival(OS), though not statistically significant. Early transplantation or FLT3 inhibitor therapy led to longer OS and event-free survival(EFS). Insertion sites located in Hinge Region(HR)/β1 domain and juxtamembrane domain (JMD) derived significantly greater benefit from early FLT3 inhibitor therapy(primarily sorafenib), showing significantly prolonged overall survival. HR/β1 insertion and multiple insertions showed a trend toward being risk factors for EFS. While white blood cell count > 30 × 10⁹/L and insertion of FLT3-ITD in the HR/β1 site were independent risk factors affecting patients' overall survival. Patients with high white blood cell counts and HR/β1 insertions demonstrated shorter overall survival, while early administration of FLT3 inhibitors resulted in significantly prolonged overall survival in this population. Early transplantation and FLT3 inhibitor therapy significantly improved prognosis in AML patients. In the era of FLT3-ITD targeted drug therapy combined with transplantation, the insertion site of FLT3-ITD based on high throughput sequencing results helps predict the efficacy of FLT3 inhibitors. Integrating white blood cell count with HR/β1 insertion site can identify a high-risk patient subgroup likely to benefit from FLT3 inhibitor therapy. - Source: PubMed
Publication date: 2026/01/15
Zhang KainanMa XiaohangLu XiaoxuanRuan GuoruiWei FangfangJiang HaoChang YingjunHuang XiaojunZhao Xiaosu